![]() ![]() “We are narrowing in on what would be a great target buyer for our product, but with customers in all different industries, it demonstrates the need for a product like this, especially with more people working remotely,” she added. works with customers across a broad range of industries from real estate to insurance to retail. It will be used to build on the product and invest in development, Habib said. The investment was led by Upfront Ventures, Aspect Ventures, Bonfire VC and Broadway Angels. The startup, which changed its name from Qordoba in August, raised a $5.2 million seed round to develop its artificial intelligence platform so that companies can analyze and correct their written language. “We think of it as a content design system where marketing teams can take control of their messaging and brand by centralizing all of their guidelines,” said May Habib, co-founder and CEO, in an interview. “We want to measure more proteins to help them do that, and pharma companies are eager for a solution and are very interested in what we are doing.” Ĭompany marketing teams spend a lot of time creating their brands, and makes sure that language, terminology and messaging are consistently communicated to anyone who writes content for the company. “When you are making something relevant to treating a disease, it is a big bet you are making,” he said. For example, the proteins could be programmed to go into a cancerous tumor, but not into healthy tissue, or go into the brain, but not another area. In addition, there are a lot of opportunities with proteins because they can be programmed to do specific tasks with the right tools, he said. Manifold Bio is not focusing yet on certain diseases, and Kuznetsov said his vision is for Manifold to be making its own therapeutics. The investment will enable the company to expand the team, accelerate the development of a proprietary protein quantitation platform and initiate partnerships with pharmaceutical companies. The startup raised a $5.4 million seed investment round led by Playground Global and joined by existing investors Fifty Years, GETTYLAB and Allston Venture Fund. “We want to predict what a drug is going to do, and we can get the best data during animal trials before the bottleneck happens when it moves to human trials,” CEO Gleb Kuznetsov, Ph.D., told Crunchbase News. Boston-based Manifold Bio, a spinoff from George Church’s lab at Harvard Medical School, is focused on increasing the number of tests that can be performed on protein therapeutics. Testing proteins is one way to see how well a drug candidate will work in humans. Subscribe to the Crunchbase Daily Manifold Bio Crunchbase News typically covers larger funding rounds, however we think these startups are worth highlighting for their interesting approaches despite their smaller raises. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |